Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Jasper Therapeutics price target lowered to $8 from $21 at Oppenheimer » 06:39
11/14/22
11/14
06:39
11/14/22
06:39
JSPR

Jasper Therapeutics

/

+

Oppenheimer analyst Jay…

Oppenheimer analyst Jay Olson lowered the firm's price target on Jasper Therapeutics to $8 from $21 and keeps an Outperform rating on the shares following quarterly results. The analyst notes the company continues to make progress on JSP191 across multiple opportunities, including recently reported promising data in the first two Fanconi Anemia patients. A registrational study in AML and MDS is on track for Q1 2023 initiation, Olson adds.

ShowHide Related Items >><<
JSPR Jasper Therapeutics
/

+

JSPR Jasper Therapeutics
/

+

10/31/22 EF Hutton
Jasper Therapeutics initiated with a Buy at EF Hutton
02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
JSPR Jasper Therapeutics
/

+

Earnings
Jasper Therapeutics reports Q3 EPS (32c), consensus (34c) » 17:02
11/10/22
11/10
17:02
11/10/22
17:02
JSPR

Jasper Therapeutics

/

+

Reports Q 3 sash and cash…

Reports Q 3 sash and cash equivalents as of September 30 were $51M compared to $84.7M as of December 31, 2021. The Company expects current cash and cash equivalents to be sufficient to fund its planned operating and capital expenditures through early 2023.

ShowHide Related Items >><<
JSPR Jasper Therapeutics
/

+

JSPR Jasper Therapeutics
/

+

10/31/22 EF Hutton
Jasper Therapeutics initiated with a Buy at EF Hutton
02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
JSPR Jasper Therapeutics
/

+

Over a month ago
Initiation
Jasper Therapeutics initiated with a Buy at EF Hutton » 16:34
10/31/22
10/31
16:34
10/31/22
16:34
JSPR

Jasper Therapeutics

/

+

EF Hutton analyst Michael…

EF Hutton analyst Michael King initiated coverage of Jasper Therapeutics with a Buy rating and $4 price target. Jasper is developing JSP191, a monoclonal antibody directed toward the CD117 receptor on stem cells that serves as a less-toxic conditioning agent for bone marrow transplantation, King tells investors in a research note. The analyst believes JSP191 has the ability to not only improve the therapeutic benefit to patients undergoing bone marrow transplantation for a variety of hematologic conditions but also expand the size of the addressable population based on the drug's "benign" safety profile.

ShowHide Related Items >><<
JSPR Jasper Therapeutics
/

+

JSPR Jasper Therapeutics
/

+

02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
JSPR Jasper Therapeutics
/

+

Syndicate
Jasper Therapeutics files $150M mixed securities shelf  16:08
10/07/22
10/07
16:08
10/07/22
16:08
JSPR

Jasper Therapeutics

/

+

 
ShowHide Related Items >><<
JSPR Jasper Therapeutics
/

+

JSPR Jasper Therapeutics
/

+

02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
JSPR Jasper Therapeutics
/

+

Conference/Events
William Blair biotech analysts to hold analyst/industry webinar » 16:25
09/29/22
09/29
16:25
09/29/22
16:25
JSPR

Jasper Therapeutics

/

+

Biotechnology Analysts,…

Biotechnology Analysts, along with Wendy Pang, SVP-Research & Translational Medicine of Jasper Therapeutics, participate in an Analyst/Industry webinar to be held on September 29 at 5 pm. Webcast Link

ShowHide Related Items >><<
JSPR Jasper Therapeutics
/

+

JSPR Jasper Therapeutics
/

+

02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
JSPR Jasper Therapeutics
/

+

Conference/Events
William Blair biotech analysts to hold analyst/industry webinar » 04:55
09/29/22
09/29
04:55
09/29/22
04:55
JSPR

Jasper Therapeutics

/

+

Biotechnology Analysts,…

Biotechnology Analysts, along with Wendy Pang, SVP-Research & Translational Medicine of Jasper Therapeutics, participate in an Analyst/Industry webinar to be held on September 29 at 5 pm. Webcast Link

ShowHide Related Items >><<
JSPR Jasper Therapeutics
/

+

JSPR Jasper Therapeutics
/

+

02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
JSPR Jasper Therapeutics
/

+

Hot Stocks
Jasper announces clinical data from invesigator sponsored study of JSP191 » 08:21
09/26/22
09/26
08:21
09/26/22
08:21
JSPR

Jasper Therapeutics

/

+

Jasper Therapeutics…

Jasper Therapeutics announced that data from the company's investigator-sponsored study of JSP191 as a conditioning agent in the treatment of Fanconi Anemia were presented at the annual conference of the Inborn Errors Working Party, a research group of the European Society of Blood and Marrow Transplantation, held on September 23-25, 2022, in Paris, France. The study is a Phase 1/2 clinical trial utilizing JSP191 to treat Fanconi Anemia patients in bone marrow failure requiring allogeneic transplant with non-sibling donors. The objective of the study is to develop cell therapy for Fanconi Anemia which enables enhanced donor hematopoietic and immune reconstitution with decreased toxicity by transplanting TCR ab+ T-cell/CD19+ B-cell depleted stem cells from a donor, after using JSP191 as a part of conditioning. Primary outcome measures include the number of patients without treatment-emergent adverse events following the administration of JSP191. In the data series presented, 100% complete donor chimerism was achieved through six months for the first patient and at one month for the second patient. Neutrophil engraftment was reached on day 11 for both patients and platelet engraftment was achieved on days 9 and 14. JSP191 was cleared by day 9 after dosing and no treatment-related adverse events or toxicities were observed.

ShowHide Related Items >><<
JSPR Jasper Therapeutics
/

+

JSPR Jasper Therapeutics
/

+

02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
JSPR Jasper Therapeutics
/

+

Conference/Events
William Blair biotech analysts to hold analyst/industry webinar » 16:27
09/22/22
09/22
16:27
09/22/22
16:27
JSPR

Jasper Therapeutics

/

+

Biotechnology Analysts,…

Biotechnology Analysts, along with Wendy Pang, SVP-Research & Translational Medicine of Jasper Therapeutics, participate in an Analyst/Industry webinar to be held on September 29 at 5 pm. Webcast Link

ShowHide Related Items >><<
JSPR Jasper Therapeutics
/

+

JSPR Jasper Therapeutics
/

+

02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
JSPR Jasper Therapeutics
/

+

Hot Stocks
Jasper Therapeutics receives fast track designation for JSP191 » 08:04
09/15/22
09/15
08:04
09/15/22
08:04
JSPR

Jasper Therapeutics

$1.37 /

-0.26 (-15.95%)

Jasper Therapeutics…

Jasper Therapeutics announced that JSP191, an anti-CD117 monoclonal antibody, has received fast track designation from the U.S. Food and Drug Administration for the treatment of patients with severe combined immunodeficiency undergoing allogeneic hematopoietic stem cell transplant. To date, JSP191 has been studied in 14 SCID patients in an ongoing multicenter clinical trial with clinical outcome data presented at academic medical conferences.

ShowHide Related Items >><<
JSPR Jasper Therapeutics
$1.37 /

-0.26 (-15.95%)

JSPR Jasper Therapeutics
$1.37 /

-0.26 (-15.95%)

02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
JSPR Jasper Therapeutics
$1.37 /

-0.26 (-15.95%)

Over a quarter ago
Earnings
Jasper Therapeutics reports Q2 EPS (29c), consensus (31c) » 16:07
08/12/22
08/12
16:07
08/12/22
16:07
JSPR

Jasper Therapeutics

$2.29 /

+0.09 (+4.10%)

"During our second…

"During our second quarter, we continued to advance multiple clinical programs for our anti-CD117 monoclonal antibody, JSP191, announcing the first patient enrolled in a trial in Fanconi Anemia, advancing our new registration trial in older patients with AML and MDS, advancing our new trial as a therapeutic agent in lower-risk transplant ineligible MDS patients and making progress on a potential BLA filing for the SCID re-transplant population," said Ronald Martell, President, and CEO of Jasper Therapeutics. "There is a compelling need for a new agent targeting hematopoietic stem cells with enhanced disease control and minimal toxicities. Based on the encouraging data in older patients with AML or MDS we presented earlier this year at the Transplantation & Cellular Therapy (TCT) annual meeting showing direct depletion of diseased stem and progenitor cells, successful donor transplant, reduction or elimination of minimal residual disease, as well as positive feedback from the FDA, we believe we have a clear path forward to initiate a registrational study of JPS191 for transplant eligible, older AML patients. We also believe that this data shows that JSP191 has the potential to be used as a therapeutic agent in patients with low to intermediate risk MDS who are not eligible for stem cell transplant and plan to initiate a clinical study later this year. JSP191 has the potential to significantly improve stem cell disease control and transplantation, and we are hopeful that our progress will lead to a major step forward in providing a new therapy for patients across a spectrum of stem cell-related diseases."

ShowHide Related Items >><<
JSPR Jasper Therapeutics
$2.29 /

+0.09 (+4.10%)

JSPR Jasper Therapeutics
$2.29 /

+0.09 (+4.10%)

02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
02/28/22 Cantor Fitzgerald
Jasper Therapeutics initiated with an Overweight at Cantor Fitzgerald
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
11/08/21 Credit Suisse
Jasper Therapeutics initiated with an Outperform at Credit Suisse
JSPR Jasper Therapeutics
$2.29 /

+0.09 (+4.10%)

JSPR Jasper Therapeutics
$2.29 /

+0.09 (+4.10%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.